Cáncer esofagogástrico en la era de inmunoterapia y terapias blanco

Molecularly directed therapy and immunotherapy in esophagogastric cancer

Contenido principal del artículo

Pedro Luis Ramos


Los datos de descargas todavía no están disponibles.

Detalles del artículo

Biografía del autor/a (VER)

Pedro Luis Ramos, Clínica Sanitas Oncocare

MD. MSc. Medicina Interna-Oncología

Referencias (VER)

National Cancer Institute SEER. Cancer Statistics. [Internet]. March 2011. Disponible en: http://www.seer.cancer.gov/statistics/.

Devesa SS, Blot WJ, Fraumeni JF Jr. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer. [Internet]. 1998;83(10):2049-53. Disponible en: https://doi.org/10.1002/(SICI)1097-0142(19981115)83:10%3C2049::AID-CNCR1%3E3.0.CO;2-2

Salvon-Harman JC, Cady B, Nikulasson S, Khettry U, Stone M, Lavin P. Shifting proportions of gastric adenocarcinomas. Arch Surg. [Internet]. 1994;129(4):381-389. Disponible en: https://doi.org/10.1001/archsurg.1994.01420280053007

Wijnhoven BP, Siersema PD, Hop WC, van Dekken H, Tilanus HW. Adenocarcinomas of the distal oesophagus and gastric cardia are one clinical entity. Br J Surg. [Internet]. 1999;86(4):529-535. Disponible en: https://doi.org/10.1046/j.1365-2168.1999.01082.x

Lu Z, Fang Y, Liu C, Zhang X, Xin X, He Y. Early Interdisciplinary Supportive Care in Patients With Previously Untreated Metastatic Esophagogastric Cancer: A Phase III Randomized Controlled Trial. J Clin Oncol. [Internet]. 2021;39(7):748-756. Disponible en: https://doi.org/10.1200/JCO.20.01254

Wang K, Johnson A, Ali SM, Klempner Sj, Bekaii-Saa T, Vacirca JL, Khaira D, Telensky R, Chmielecki J, Elvin JA, et al. Comprehensive Genomic Profiling of Advanced Esophageal Squamous Cell Carcinomas and Esophageal Adenocarcinomas Reveals Similarities and Differences. Oncologist. [Internet]. 2015;20(10):1132-1139. Disponible en: https://doi.org/10.1634/theoncologist.2015-0156

Chau I, Doki Y, Ajani JA, et al. Nivolumab (NIVO) plus ipilimumab (IPI) or NIVO plus chemotherapy (chemo) versus chemo as firs t-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): First results of the CheckMate 648 study (abstr act). J Clin Oncol. [Internet]. 39, 2021 (suppl 15; abstr LBA4001). Disponible en: https://doi.org/10.6004/jadpro.2021.12.6.6

Sun JM, Shen L, Shah MA, Enzinger P, Adenis A, Doi T,et al. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. The Lancet. [Internet]. 2021;398(10302):759-771. Disponible en: https://doi.org/10.1016/S0140-6736(21)01234-4

Xu R-H, Luo H, Lu J, Bai Y, Mao T, Wang J, et al. ESCORT-1st: A randomized, double-blind, placebo-controlled, phase 3 trial of camrelizumab plus che motherapy versus chemotherapy in patients with untreated advanced or metastatic esophageal squamous cell carcinoma (ES CC) (abstract). J Clin Oncol. [Internet]. 2021;39 (15 suppl): abstr 4000. Disponible en: https://doi.org/10.1200/JCO.2021.39.15_suppl.4000

Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. [Internet]. 2010;376:687-97. Disponible en: https://doi.org/10.1016/S0140-6736(10)61121-X

Janjigian YY, Kawazoe A, Yanez PE, Luo S, Leonardi S, Kolesnik O, et al. Pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction (G/GEJ) cancer: Initial findings of the global phase 3 KEYNOTE-811 study (abstract). J clin Oncol. [Internet]. 2021;39 (15 suppl; abstr 4013). Disponible en: https://doi.org/10.1200/JCO.2021.39.15_suppl.4013

Shitara K, Van Cutsem E, Bang YJ, Fuchs C, Wyrwicz L, Lee KW, Castro HR, Garrido, M, et al. Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial. JAMA Oncol. [Internet]. 2020;6(10):1571-1580. Disponible en: https://doi.org/10.1001/jamaoncol.2020.3370

Chao J, Fuchs CS, Shitara K, Tabernero J, Muro K, Cutsem EV, Bang YJ, De Vita F, Landers G, et al. Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instability-High Gastric or Gastroesophageal Junction Cancer Among Patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical Trials. JAMA Oncol. [Internet]. 2021;7(6):895-902. Disponible en: https://doi.org/10.1001/jamaoncol.2021.0275

Moehler M, Shitara K, Garrido M, et al. LBA6_PR - Nivolumab (nivo) plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC)/esophageal adenocarcinoma (EAC): First results of the CheckMate 649 study. Ann Oncol. [Internet]. 2020;31S:ESMO #S1142. https://doi.org/10.1016/j.annonc.2020.08.2296

Ajani JA, Ilson DH, Daugherty K, Pazdur R, Lynch PM, Kelsen DP. Activity of taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus. J Natl Cancer Inst. [Internet]. 1994;86(14):1086-1091. Disponible en: https://doi.org/10.1093/jnci/86.14.1086

Mavroudis D, Kourousis C, Androulakis N, Kalbakis K, Agelaki S, Kakolyris S, Souglakos J, Sarra, E, Vardakis N, Hatzidaki D, Sarmonis G, Georgoulias V. Frontline treatment of advanced gastric cancer with docetaxel and granulocyte colony-stimulating factor (G-CSF): a phase II trial. Am J Clin Oncol. [Internet]. 2000;23(4):341-344. Disponible en: https://doi.org/10.1097/00000421-200008000-00005

Sulkes A, Smyth J, Sessa C, Dirix LY, Vermorken JB, Kaye S, Wanders J, Franklin H, LeBail N, Verweij J. Docetaxel (TaxotereTM) in advanced gastric cancer: results of a phase II clinical trial. EORTC Early Clinical Trials Group. Br J Cancer. [Internet]. 1994;70:380-383. Disponible en: https://doi.org/10.1038/bjc.1994.310

Kato K, Tahara M, Hironaka S, Muro K, Takiuchi H, Hamamoto Y, Imamoto H, Amano N, Sriu T. A phase II study of paclitaxel by weekly 1-h infusion for advanced or recurrent esophageal cancer in patients who had previously received platinum-based chemotherapy. Cancer Chemother Pharmacol. [Internet]. 2011;67:1265-1272. Disponible en: https://doi.org/10.1007/s00280-010-1422-x

Kii T, Takiuchi H, Gotoh M, Kawabe S, Ohta S, Tanaka T, Kuwakado S, Nishitani H, Katsu K. [Weekly administration regimen of paclitaxel (PTX) in patient with inoperable or recurrent gastric cancer]. Gan To Kagaku Ryoho. 2006;33(5):621-4. Japanese. PMID: 16685160.

Köhne CH, Catane R, Klein B, Ducreux M, Thuss-Patience P, Niederle N, Gips M, Preusser P, Knuth A, Clemmens M, et al. Irinotecan is active in chemonaive patients with metastatic gastric cancer: a phase II multicentric trial. Br J Cancer. [Internet]. 2003;89:997-1001. Disponible en: https://doi.org/10.1038/sj.bjc.6601226

Enzinger PC, Kulke MH, Clark JW, Ryan DP, Kim H, Earle CC, Vicitore MM, Michelini AL, Mayer R, Fuchs CS. A phase II trial of irinotecan in patients with previously untreated advanced esophageal and gastric adenocarcinoma. Dig Dis Sci. [Internet]. 2005;50:2218-2223. https://doi.org/10.1007/s10620-005-3038-2

Kok TC, van der Gaast A, Splinter TA. Rotterdam Esophageal Tumor Study Group. 5-fluorouracil and folinic acid in advanced adenocarcinoma of the esophagus or esophago-gastric junction area. Ann Oncol. [Internet]. 1996;7:533-534. Disponible en: https://doi.org/10.1093/oxfordjournals.annonc.a010646

Alberts AS, Schoeman L, Burger W, Greef F, Falkson G. A phase II study of 5-fluorouracil and leucovorin in advanced carcinoma of the esophagus. Am J Clin Oncol. [Internet]. 1992;15(1):35-36. Disponible en: https://doi.org/10.1097/00000421-199202000-00007

Hara H, Kadowaki S, Asayama M, Ooki A, Yamada T, Yoshii T, Yamaguchi K. First-line bolus 5-fluorouracil plus leucovorin for peritoneally disseminated gastric cancer with massive ascites or inadequate oral intake. Int J Clin Oncol. [Internet]. 2018;23:275-280. Disponible en: https://doi.org/10.1007/s10147-017-1198-7

Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubistein L, Shankar L, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. [Internet]. 2009;45(2):228-47. Disponible en: https://doi.org/10.1016/j.ejca.2008.10.026

Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan R, Rubinstein L, Verwrji, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. [Internet]. 2000;92(3):205-216. Disponible en: https://doi.org/10.1093/jnci/92.3.205

Park SR, Kim MJ, Nam BH, Cho SJ, Kong SY, Park YL. A randomised phase II study of continuous versus stop-and-go S-1 plus oxaliplatin following disease stabilisation in first-line chemotherapy in patients with metastatic gastric cancer. Eur J Cancer. [Internet]. 2017;83:32-42. Disponible en: https://doi.org/10.1016/j.ejca.2017.06.008

Citado por